ReviewFrontiers in immunology2025
Mechanistic and therapeutic insights into the function of different cell death modalities in rheumatoid arthritis: emphasis on the crosstalk with non-coding RNAs.
Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The "Tianyu" Formulation Alleviates Rheumatoid Arthritis by Modulating the NLRP3/Caspase-1/GSDMD-Mediated Pyroptosis Pathway.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Article
- SIRT1 as a Key Regulator in Rheumatic Diseases: Integrating Molecular Insights with Traditional Chinese Medicine Approaches.Journal of inflammation research · 2026Review
- Bridging Pharmacology and Nanotechnology: Mechanistic Insights into Traditional Chinese Medicine-Based Nanodelivery Systems for Rheumatoid Arthritis.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rheumatoid arthritis (RA), a prevalent autoimmune disorder, imposes a substantial burden on global health due to its progressive disability and compromised patient well-being. Although the precise etiology of this condition is still not fully understood, current research implicates intricate interactions between dysregulated immune cells and pro-inflammatory mediators. Recent scientific advancements have highlighted the pathogenic significance of programmed cell death (PCD) mechanisms (including spanning apoptosis, autophagy, ferroptosis, necroptosis, senescence, and pyroptosis) in RA pathophysiology. Emerging evidence has established these cellular demise pathways as critical contributors to synovial inflammation and joint destruction. This comprehensive analysis systematically examined the mechanistic involvement of distinct cell death modalities in RA development, with particular focus on their regulatory interplay with non-coding RNAs (ncRNAs). Furthermore, the emerging therapeutic potential of traditional Chinese medicine (TCM) formulations in modulating these cell death networks was evaluated, ultimately proposing novel translational frameworks for targeted RA intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.